智通港股早知道 | CXO板块有望获业绩支撑 昭衍新药(06127)预计上半年归母净利润同比增加884.9%到1377.4%
Last Update:
15 7 月, 2026
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.